Genetic Variation in TRAF3IP2 (rs13190932)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSouth Valley University
About this trial
Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population.
It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals.
The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients aged 18 -70years .
the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist.
Willingness to participate: Signed informed consent.
Initiating methotrexate (MTX) therapy: For prospective cohort.
Disqualifiers
Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
Pregnancy and lactation.
Patients currently undergoing immunosuppressive or systemic therapies.
Patients with known genetic disorders affect immune system function.
Trial design
Design model
Parallel
Treatments tested in this trial
Methotrexate
DrugAssessing the response of psoriasis and psoriatic arthritis to Methotrexate. and also Assessing the pharmacogenetic association between TRAF3IP2 ( rs13190932 ) gene Polymorphism in psoriatic and psoriatic arthritis patients taking Methotrexate.
Treatment groups
50 Participants
are divided into 3 treatment groupsGroup A: Group AActive comparator 1 intervention
Group B: Group BActive comparator 1 intervention
Group C: Group CExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Treatment of Psoriasis and Psoriatic arthritis
Treatment the patients whom suffering from Psoriasis and Psoriatic arthritis and Assessment of clinical improvement to methotrexate therapy according to: PASI score into PASI 50: means 50% reduction in PASI score - an acceptable measure of efficacy for secondary endpoints in psoriasis clinical trials PASI 75: means 75% reduction in PASI score - standard efficacy measure used in most psoriasis clinical studies1 PASI 90: means 90% reduction in PASI score (almost clear skin) PASI 100: means Completely clear skin.
Time frame
3 months2
Evalaute the effect of treatment with Methotrexate
Evaluate the effect of treatment with methotrexate therapy (15 mg per week) on the level of serum TRAF3IP2( rs13190932 ) gene Polymorphism on the Participants whom suffering from Psoriasis and Psoriatic arthritis.
Time frame
3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov